StockData
Aquestive Therapeutics, Inc. logo

Aquestive Therapeutics, Inc. (AQST) stock

AQSTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 3/30
$3.70−0.06 (-1.60%)

Close on Nov 17, 2026Market cap $464.39MP/E –Yield –

Aquestive Therapeutics cash

Cash and short-term investments held at the end of each period.

Aquestive Therapeutics's cash was $98.49M at Jun 30, 2026. For fiscal 2025 it was $121.17M, up 69.4% from the year before. The highest annual figure on record is $121.17M in fiscal 2025.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$121.17M+69.4%
FY2024Dec 31, 2024$71.55M+199.7%
FY2023Dec 31, 2023$23.87M-12.5%
FY2022Dec 31, 2022$27.27M-2.7%
FY2021Dec 31, 2021$28.02M-11.9%
FY2020Dec 31, 2020$31.81M-35.5%
FY2019Dec 31, 2019$49.33M-18.6%
FY2018Dec 31, 2018$60.60M+248.7%
FY2017Dec 31, 2017$17.38M+88.7%
FY2016Dec 31, 2016$9.21M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$98.49M+62.7%
Q1 FY2026Mar 31, 2026$110.73M+61.3%
Q4 FY2025Dec 31, 2025$121.17M+69.4%
Q3 FY2025Sep 30, 2025$129.06M+65.7%
Q2 FY2025Jun 30, 2025$60.54M-32.6%
Q1 FY2025Mar 31, 2025$68.66M-27.9%
Q4 FY2024Dec 31, 2024$71.55M+199.7%
Q3 FY2024Sep 30, 2024$77.89M+212.6%
Q2 FY2024Jun 30, 2024$89.87M+300.6%
Q1 FY2024Mar 31, 2024$95.20M+254.1%
Q4 FY2023Dec 31, 2023$23.87M-12.5%
Q3 FY2023Sep 30, 2023$24.92M+33.6%
Q2 FY2023Jun 30, 2023$22.44M+26.8%
Q1 FY2023Mar 31, 2023$26.88M+82.4%
Q4 FY2022Dec 31, 2022$27.27M-2.7%
Q3 FY2022Sep 30, 2022$18.65M-40.2%
Q2 FY2022Jun 30, 2022$17.70M-48.3%
Q1 FY2022Mar 31, 2022$14.74M-46.4%
Q4 FY2021Dec 31, 2021$28.02M-11.9%
Q3 FY2021Sep 30, 2021$31.16M+82.6%
Q2 FY2021Jun 30, 2021$34.23M+34.7%
Q1 FY2021Mar 31, 2021$27.50M-22.6%
Q4 FY2020Dec 31, 2020$31.81M-35.5%
Q3 FY2020Sep 30, 2020$17.06M-18.4%
Q2 FY2020Jun 30, 2020$25.42M+14.7%
Q1 FY2020Mar 31, 2020$35.52M-11.1%
Q4 FY2019Dec 31, 2019$49.33M-18.6%
Q3 FY2019Sep 30, 2019$20.91M-67.3%
Q2 FY2019Jun 30, 2019$22.17M+34.4%
Q1 FY2019Mar 31, 2019$39.93M+129.8%
Q4 FY2018Dec 31, 2018$60.60M+138.2%
Q3 FY2018Sep 30, 2018$63.98M+521.8%
Q1 FY2018Mar 31, 2018$16.49M+79.0%
Q4 FY2017Dec 31, 2017$17.38M–
Q3 FY2017Sep 30, 2017$25.44M–
Q2 FY2017Jun 30, 2017$10.29M–
Q4 FY2016Dec 31, 2016$9.21M–

More Aquestive Therapeutics figures

See a number that looks wrong?